The a16z Show Undruggable Drugs
34 snips
May 6, 2020 Jay Bradner, President of the Novartis Institute for BioMedical Research, reveals cutting-edge advancements in drug development. He discusses the challenges of targeting 'undruggable' proteins and how innovative techniques like molecular glues and gene therapies are revolutionizing therapeutic possibilities. Bradner shares breakthroughs focused on previously inaccessible targets, like SHIP2, and emphasizes the importance of collaboration in this field. Insights into the science behind drug discovery shine a light on the future of treatment for serious diseases.
AI Snips
Chapters
Transcript
Episode notes
Understanding vs. Approaching Targets
- Undruggable targets are not always due to a lack of biological understanding.
- The challenge lies in finding ways to approach and interact with these targets, like MYC in cancer.
SHIP2: An "Undruggable" Success
- Novartis developed the first inhibitor of a phosphatase, SHIP2, previously considered "undruggable."
- This was achieved by targeting an allosteric site instead of the active site, effectively "gluing" the protein.
Proteins: Dynamic, Not Static
- Proteins are dynamic, not static, which opens up new possibilities for drug targeting.
- Allosteric sites and the concept of "molecular glues" exploit this dynamic nature.